Cara touts sub­group in failed atopic der­mati­tis tri­al, but stock craters

Cara Ther­a­peu­tics will join the grow­ing list of biotech to launch a Phase III de­spite fail­ing Phase II.

The itch-fo­cused com­pa­ny an­nounced Thurs­day that its cen­tral drug, a pill called Ko­r­su­va, failed to sig­nif­i­cant­ly al­le­vi­ate itch­ing in pa­tients with atopic der­mati­tis when com­pared with place­bo. The drug missed both the pri­ma­ry end­point, the change in av­er­age score on a stan­dard itch scale af­ter 12 weeks, and the key sec­ondary end­point: The pro­por­tion of pa­tients who im­proved by at least 4 points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.